Introduction:

The 2019 GINA strategy report presents the most relevant changes in asthma management in the last 30 years.

Objective:

The purpose of this article is to disseminate the changes in GINA 2019 regarding the treatment of mild asthma, and to express the position and recommendations from the members of the experts for awareness of asthma in Mexico.

Methodology:

A group of opinion leaders and asthma experts in Mexico was brought together to discuss the studies and evidence that support the changes in GINA 2019.

Results:

Positions and strategies were defined to address the different challenges posed by these changes.

Conclusions:

The recommendation is that every asthma patient should receive anti-inflammatory treatment. One strategy in patients with intermittent symptoms is to use a low-dose inhaled corticosteroid/formoterol as a preferred reliever, and daily low dose ICS/formoterol both as control and rescue (as needed) treatment for patients with persistent symptoms. The results of the studies and their impact on clinical practice are promising.